论文部分内容阅读
单克隆抗体药物是一种新兴的治疗药物,具有高选择性,被用于多种疾病的治疗,如肿瘤、免疫疾病等,也可以用于中枢神经系统疾病,如阿尔茨海默病、帕金森病、中风和脑肿瘤等。然而,因为血脑屏障低通透性,限制了抗体药物在中枢神经系统疾病治疗中的应用,在很多神经系统疾病临床试验中,抗体药物并没有取得预期效果。如今,人们利用血脑屏障上内源性转运蛋白介导,设计了可以通过血脑屏障的抗体药物。对通过血脑屏障治疗性抗体药物研发进展及其应用前景进行了综述。
Monoclonal antibody drugs are emerging therapeutic drugs with high selectivity and are used in the treatment of various diseases such as tumors and immune diseases as well as in diseases of the central nervous system such as Alzheimer’s disease, Encephalopathy, stroke and brain tumors. However, the low permeability of the blood-brain barrier has limited the use of antibody drugs in the treatment of central nervous system diseases. Antibody drugs have not achieved the desired results in many clinical trials of neurological diseases. Today, people use endogenous transporters on the blood-brain barrier to mediate and design antibody drugs that cross the blood-brain barrier. The development of therapeutic antibody drugs through the blood-brain barrier and its application prospect are reviewed.